Show simple item record

dc.contributor.advisorFisher, David
dc.contributor.authorJeftha, Tershlin
dc.date.accessioned2023-11-14T08:20:04Z
dc.date.available2023-11-14T08:20:04Z
dc.date.issued2023
dc.identifier.urihttp://hdl.handle.net/11394/10551
dc.description>Magister Scientiae - MScen_US
dc.description.abstractThe blood-brain barrier (BBB) serves as a protective and regulatory barrier between the blood and the brain. Microvascular endothelial cells provide homeostatic regulation of the central nervous system (CNS). BBB integrity is compromised by inflammation, which contributes to a wide range of neurological disorders. It has been shown that glucocorticoids (GCs) have anti-inflammatory functions on a variety of cells. A particular example is Dexamethasone (Dex), which is used for the treatment of inflammatory conditions and has recently been found to be effective in attenuating COVID-19. Aim: The purpose of this study was to determine whether low or high concentrations of Dex can attenuate the inflammatory response induced by LPS on the in vitro BBB model.en_US
dc.language.isoenen_US
dc.publisherUniversity of the Western Capeen_US
dc.subjectBlood-brain barrier (BBB)en_US
dc.subjectCentral nervous system (CNS)en_US
dc.subjectLipopolysaccharide (LPS)en_US
dc.subjectCOVID-19en_US
dc.subjectInduced inflammationen_US
dc.titleDexamethasone's impact on LPS-induced inflammation of blood-brain barrier endothelial cellsen_US
dc.rights.holderUniversity of the Western Capeen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record